Literature DB >> 26306903

Targeting the WNT Signaling Pathway in Cancer Therapeutics.

David Tai1, Keith Wells1, John Arcaroli1, Chad Vanderbilt1, Dara L Aisner1, Wells A Messersmith1, Christopher H Lieu2.   

Abstract

The WNT signaling cascade is integral in numerous biological processes including embryonic development, cell cycle regulation, inflammation, and cancer. Hyperactivation of WNT signaling secondary to alterations to varying nodes of the pathway have been identified in multiple tumor types. These alterations converge into increased tumorigenicity, sustained proliferation, and enhanced metastatic potential. This review seeks to evaluate the evidence supporting the WNT pathway in cancer, the therapeutic strategies in modulating this pathway, and potential challenges in drug development. ©AlphaMed Press.

Entities:  

Keywords:  Drug development; Frizzled; Signal transduction; WNT; β-Catenin

Mesh：

Substances：

Year:  2015        PMID： 26306903      PMCID： PMC4591954          DOI： 10.1634/theoncologist.2015-0057

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  72 in total

1.  Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling.

Authors:  W Liu; X Dong; M Mai; R S Seelan; K Taniguchi; K K Krishnadath; K C Halling; J M Cunningham; L A Boardman; C Qian; E Christensen; S S Schmidt; P C Roche; D I Smith; S N Thibodeau
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

2.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.

Authors:  M J Hart; R de los Santos; I N Albert; B Rubinfeld; P Polakis
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

Review 3.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

4.  Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Authors:  Travis L Biechele; Rima M Kulikauskas; Rachel A Toroni; Olivia M Lucero; Reyna D Swift; Richard G James; Nick C Robin; David W Dawson; Randall T Moon; Andy J Chien
Journal:  Sci Signal       Date:  2012-01-10       Impact factor: 8.192

5.  Deficiency of Mbd2 suppresses intestinal tumorigenesis.

Authors:  Owen J Sansom; Jennifer Berger; Stefan M Bishop; Brian Hendrich; Adrian Bird; Alan R Clarke
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 6.  A Wnt-er migration: the confusing role of β-catenin in melanoma metastasis.

Authors:  Marie R Webster; Ashani T Weeraratna
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

7.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Authors:  Katayoon H Emami; Cu Nguyen; Hong Ma; Dae Hoon Kim; Kwang Won Jeong; Masakatsu Eguchi; Randall T Moon; Jia-Ling Teo; Se Woong Oh; Hak Yeop Kim; Sung Hwan Moon; Jong Ryul Ha; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

8.  Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.

Authors:  Gunhild M Maelandsmo; Ruth Holm; Jahn M Nesland; Øystein Fodstad; Vivi Ann Flørenes
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 9.  Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors.

Authors:  Wilson M Clements; Andrew M Lowy; Joanna Groden
Journal:  Clin Colorectal Cancer       Date:  2003-08       Impact factor: 4.481

10.  The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Authors:  Caroline E Ford; Eve Jary; Sean Si Qian Ma; Sheri Nixdorf; Viola A Heinzelmann-Schwarz; Robyn L Ward
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240
View more
  49 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

Review 2.  Pathway perturbations in signaling networks: Linking genotype to phenotype.

Authors:  Yongsheng Li; Daniel J McGrail; Natasha Latysheva; Song Yi; M Madan Babu; Nidhi Sahni
Journal:  Semin Cell Dev Biol       Date:  2018-05-10       Impact factor: 7.727

Review 3.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

4.  Differentially expressed lncRNAs in peripheral blood mononuclear cells from middle-aged female patients with rheumatoid arthritis-associated interstitial lung disease.

Authors:  Wei Zhou; Juan Zheng; Min Yuan; Lindong Yuan; Xiaodong Jia; Huaxiang Liu
Journal:  Clin Rheumatol       Date:  2020-03-05       Impact factor: 2.980

Review 5.  Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.

Authors:  Jerry Harb; Pen-Jen Lin; Jijun Hao
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

6.  Synergistic antitumor efficacy of antibacterial helvolic acid from Cordyceps taii and cyclophosphamide in a tumor mouse model.

Authors:  Jian-Hui Xiao; Yao Zhang; Gui-You Liang; Ru-Ming Liu; Xiao-Gang Li; Ling-Tao Zhang; Dai-Xiong Chen; Jian-Jiang Zhong
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 7.  Pharmacological and immunological targeting of tumor mesenchymalization.

Authors:  Justin M David; Charli Dominguez; Claudia Palena
Journal:  Pharmacol Ther       Date:  2016-12-01       Impact factor: 12.310

8.  Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.

Authors:  Amei Schweigert; Carmen Fischer; Doris Mayr; Dietrich von Schweinitz; Roland Kappler; Jochen Hubertus
Journal:  Pediatr Surg Int       Date:  2016-09-27       Impact factor: 1.827

Review 9.  Research Advances of Germinal Matrix Hemorrhage: An Update Review.

Authors:  Jinqi Luo; Yujie Luo; Hanhai Zeng; Cesar Reis; Sheng Chen
Journal:  Cell Mol Neurobiol       Date:  2018-10-25       Impact factor: 5.046

Review 10.  Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers.

Authors:  Dustin J Flanagan; Elizabeth Vincan; Toby J Phesse
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.